Insider · CIK 0001583886
Steven Frank
director
Files at BCRX (BIOCRYST PHARMACEUTICALS INC), PGEN (PRECIGEN, INC.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 31, 2026 | BCRX BIOCRYST PHARMACEUTICALS INC | AGrant or award Common Stock | +1,288 | $9.70 | $12k | 36,747 | 40 d ago |
| Jun 12, 2025 | BCRX BIOCRYST PHARMACEUTICALS INC | AGrant or award Common Stock | +12,500 | $0.00 | $0 | 14,699 | Jun 16, 2025 |
| Jun 12, 2025 | BCRX BIOCRYST PHARMACEUTICALS INC | AGrant or award Automatic Stock Option Grantderivative | +27,181 | $0.00 | $0 | 27,181 | Jun 16, 2025 |
| May 30, 2025 | BCRX BIOCRYST PHARMACEUTICALS INC | AGrant or award Common Stock | +333 | $10.75 | $3,580 | 2,199 | Jun 3, 2025 |
| May 2, 2025 | BCRX BIOCRYST PHARMACEUTICALS INC | AGrant or award Common Stock | +1,866 | $0.00 | $0 | 1,866 | May 6, 2025 |
| May 2, 2025 | BCRX BIOCRYST PHARMACEUTICALS INC | AGrant or award Automatic Stock Option Grantderivative | +4,079 | $0.00 | $0 | 4,079 | May 6, 2025 |
| Mar 13, 2025 | PGEN PRECIGEN, INC. | AGrant or award Common Stock | +28,735 | $1.74 | $50k | 1,052,895 | Mar 17, 2025 |
| Mar 14, 2025 | PGEN PRECIGEN, INC. | MOption exercise Common Stock | +87,412 | - | - | 1,140,307 | Mar 17, 2025 |
| Mar 13, 2025 | PGEN PRECIGEN, INC. | AGrant or award Restricted Stock Unitsderivative | +71,839 | $0.00 | $0 | 71,839 | Mar 17, 2025 |
| Mar 14, 2025 | PGEN PRECIGEN, INC. | MOption exercise Restricted Stock Unitsderivative | -87,412 | $0.00 | $0 | 0 | Mar 17, 2025 |
| Mar 13, 2025 | PGEN PRECIGEN, INC. | AGrant or award Option to Purchase Common Stock (Right to Buy)derivative | +83,517 | $0.00 | $0 | 83,517 | Mar 17, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.